GlaxoSmithKline PLC's 'bubble boy' treatment has been given a positive opinion by the European Medicines Agency's advisory committee.
GlaxoSmithKline PLC's 'bubble boy' treatment has been given a positive opinion by the European Medicines Agency's advisory committee.
The Committee for Medicinal Products for Human Use (CHMP), in conjunction with the Committee for Advanced Therapies (CAT), recommends marketing...
Create an account to read this article
Already a subscriber?
Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.
In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.
Multi-blockbuster falls short in a giant cell arteritis study.
The drugmaker will spend up to $2.1bn to acquire the privately held biotech firm and its targeted lipid nanoparticle technology platform, with an anti-CD19 asset in the clinic.
Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
